Organisations

The Australian Prostate Cancer Research Centre – Queensland is an integrated, transdisciplinary, and comprehensive prostate cancer research centre. Based in Brisbane, the APCRC – Q is a joint venture between the Queensland University of Technology and the Princess Alexandra Hospital.

The APCRC – Q works closely with the Australian Prostate Cancer Research Centre in Victoria, as well as numerous other partner organisations. Established in 2007 by Professor Colleen Nelson, the APCRC – Q is modeled on the successful Vancouver Prostate Centre at Vancouver General Hospital in Canada, of which Prof Nelson is a co-founder.

It focuses exclusively on prostate cancer, and is a hub for prostate cancer research in Brisbane. It is assembled into a multidisciplinary framework that integrates research activities from discovery through to clinical trials.

ANZUP is a national cooperative trials group in urogenital and prostate cancer research, with funding from Cancer Australia under its Support for Cancer Clinical Trials Program.

ANZUP was formed to meet the need for greater collaboration within the Australian and New Zealand medical communities for research and clinical trials, especially for urogenital and prostate cancers.

ANZUP has numerous Australian and international collaborators, and is a multi-disciplinary organisation. It aims to find better ways to treat urogenital and prostate cancers in order to improve patient quality of life and life expectancy.

ANZUP has more than 480 members from Australia, New Zealand and internationally. Members include medical and radiation oncologists, basic scientists, urologic surgeons, clinical trial coordinators and allied health professionals.

The Centre is the provincial centre for prostate disease located at CancerCare Manitoba. It aims to coordinate timely access to a multi-disciplinary team of health care professionals for men with both benign and malignant prostate disease. This includes clinical nurse specialists, psychosocial clinician, registered dietician and oncology clinicians and surgeons.  The Centre gives assessment, diagnosis and treatment in a timely manner and provides evidence based care.   Education and supportive care is available to all patients and their families. Research is important aspect of the Centre where new knowledge is applied to new treatments for prostate cancer patients. The Centre provides clinical trials, supportive care research, populations based studies and the opportunity for patients to bank their biological tissues for future research efforts through the Manitoba Tumor Bank.

The Institute of Health and Biomedical Innovation (IHBI) is the largest research institute at the Queensland University of Technology (QUT), and is based in a unique research facility at the Kelvin Grove Urban Village in Brisbane, Australia. IHBI research encompasses three broad areas of human health - prevention, mind and body health, and recovery.

With more than 750 institute members, IHBI draws from a wide base of leading health and biomedical researchers including engineers, medical practitioners, molecular biologists, infectious disease specialists, nurses, psychologists, public health experts, vision scientists, movement physiologists and statisticians.

IHBI has ongoing links with local and interstate hospitals, health researchers worldwide, clinical specialists and industry professionals. IHBI also benefits from QUT's highly successful track record in commercial partnerships and sustainable biotechnology companies.

By working with a broad network of health and medical professionals, IHBI believes it is possible to bridge the gap between science and better health for everyone.

IHBI research is clustered into five research domains which have significant expertise in the following areas:

Cells and Tissue Domain

• Infectious Diseases: vaccine development, molecular bacteriology and virology, population biology and diagnostics

• Tissue Repair and Regeneration: dermal wound repair and regeneration; bone, connective tissue and musculoskeletal repair and regeneration; biomaterials and scaffolds; mathematical modelling of repair regeneration

• Hormone Dependent Cancer Research: prostate cancer research, ADAM 10 Protease, ghrelin and growth factors, kallikrien proteases, mollecular and cell Biology.

Human Health and Wellbeing Domain

• Social and environmental determinants of health: Australian Sun and Health Research Laboratory, psychosocial predictors of health / risk factors

• Health Services research and policy: disease screening, care and quality of care

• Chronic disease and palliative care: chronic disease management and prevention, palliative care, dementia

• Child and youth health: child protection, nutrition in early childhood
• Mental health and wellbeing: resillience and wellbeing, therapy processes and outcomes, cross-cultural and community psychology.

Injury Prevention and Rehabilitation Domain

• Accident research and road safety: human behaviour anf technology interface, vulnerable road users, road safety education, fleet and workplace safety

• Workplace injury: ergonomics and motor control

• Falls prediction and prevention

• Medical Device Domain

• Orthopaedics and trauma research: medical engineering,spine research, cartilage research

• Artifical heart pump

• Regenerative Medicine

• Medical Physics.

Vision Improvement Domain

• Diabetes and opthalmic nerve damage
• Ocular growth regulation in myopia
• Contact lens and visual optics
• Vision driving and falls
• Ocular tissues.

At Janssen, we believe that scientific innovation is critical to better health care for people around the world. Along with a strong commitment to research within our own organization, we have made a commitment to partner with universities, research institutes and companies who share our vision and with whom we can work together providing the ideas and expertise to identify, develop and commercialize the therapies of tomorrow. In addition, we continue to look for new opportunities to work with licensing or acquisition firms to further support the establishment of early stage healthcare companies developing treatments of high unmet medical need. We understand and value the potential and exceptional results these partnerships can bring. Prostate cancer is one of our core areas of scientific research and development.

Janssen has a proven track record of managing successful partnerships from early to later stage discovery and development. We view partnerships as central to our business activities and this is reflected in our professional and flexible approach. We have an ongoing commitment to deliver the best value to our partners across all stages of a product life cycle, including leveraging our strong functional expertise across clinical research and development, regulatory, health economics and pricing, product launch management, sales and marketing.

If you are interested in partnering with Janssen in early stage prostate cancer research, please contact Kathy Connell, Senior Manager Innovation and Investment at kconnel6@its.jnj.com

The Manitoba Institute of Cell Biology (MICB) was founded in 1969 jointly by CancerCare Manitoba (formerly the Manitoba Cancer Treatment and Research Foundation) and the University of Manitoba. The institute is associated with the Faculty of Medicine and the Health Sciences Centre and is located on the 5th, 6th and 7th floors of the  new CancerCare building at 675 McDermot Ave. in Winnipeg, Manitoba, Canada, R3E 0V9. The institute is dedicated to fundamental  and translational research in biology and its relation to health, with a primary emphasis on cancer and related diseases. MICB presently has 14 senior research scientists, 9 of whom are basic scientists and 5 clinician-scientists; we have 5 associate research scientists and approximately 170 support personnel and trainees. As well MICB has several core facilites or platforms such as our Manitoba Tumour Bank which includes breast, prostate, lung, head & neck tumours and  chronic  lymphocytic leukemia banks; the Genomic Centre for Cancer Research and Diagnosis; the Mammalian Functional Genomics Centre and Manitoba Breast Cancer Research Centre which includes a proteomics platform.

Prostate Cancer Canada raises funds for the development of programs related to awareness, public education, advocacy, support of those affected, and research into the prevention, detection, and treatment of prostate cancer.

The Prostate Cancer Foundation of Australia (PCFA) is the national body for prostate cancer in Australia.  PCFA plays a vital role in the fight against prostate cancer and devotes all of it resources towards reducing the impact of prostate cancer on the community.  PCFA is a registered charity (ABN 42 073 253 924).

Queensland Clinical Trials Network Inc. (QCTN) is an Australian-based, independent, not-for-profit organisation.

As a peak industry representative association, QCTN is an ‘umbrella organisation’ representing more than 70 businesses that have a presence in Queensland. These organisations are life sciences service providers and related entities serving the pharmaceutical, biotechnology, complementary medicines and medical devices industries.

As a primary point of contact for international organisations seeking to undertake preclinical and clinical drug development in Australia, QCTN helps identify and connect overseas organisations with appropriate Australian research institutes, biotechnology and medical device companies and life sciences third party service providers.

QCTN is involved in organising trade missions, seminars, industry workshops, conferences, government advocacy, establishing and maintaining relationships with other industry groups around the world.

QCTN’s aim is to promote and raise the visibility of the Australian biopharmaceutical industry and life sciences service providers at a national and international level and to support them in building their capabilities in terms of know-how, best business practices, information and human resource solutions, as well as to facilitate opportunities for in/out licensing deals, mergers and acquisitions, and marketing activities.  QCTN provides members and sponsors access to unique specialised support services including:

• Independent Human Research Ethics Committee (HREC)
• Independent Institutional Biosafety Committee (IBC)
• Nationally Recognised Training for HRECs, Researchers and Sponsors (provider number 32008).

The mission of the Vancouver Prostate Centre is to foster the paradigm of team-driven translational health research to discover molecular mechanisms of cancer progression and therapeutic resistance, and to use this information to develop new services and products that reduce suffering, improve survival for patients with cancer and promote regional growth of biotechnology.

Based on the Vancouver General Hospital (Vancouver Acute) campus in Vancouver, BC, Canada, our host institutions are the Vancouver Coastal Health Research Institute and the Faculty of Medicine at the University of British Columbia. The Vancouver Prostate Centre houses PC-TRIADD; more info on PC-TRIADD is available on its organizational profile on this website.

Our expertise, resources and technologies cover the spectrum of drug and biomarker development, including a Microarray facility, applied genomics, pre-clinical pharmacology and clinical trials. See http://pctriadd.com for further details.

The Victorian Prosate Cancer Research Consortium (VPCRC) is a dedicated research based consortium that aims to increase the level of research into understanding the fundamental mechanisms underlying prostate cancer development and contributing to treatment resistance. The aim of the consortium is to establish vibrant and meaningful research collaborations between nodes able to link biomedical and clinical research, and to span the diagnostic and therapeutic development spectrum, without investing in physical infrastructure or capital development.

The Victorian Prosate Cancer Research Consortium (VPCRC) is a dedicated research based consortium that aims to increase the level of research into understanding the fundamental mechanisms underlying prostate cancer development and contributing to treatment resistance. The aim of the consortium is to establish vibrant and meaningful research collaborations between nodes able to link biomedical and clinical research, and to span the diagnostic and therapeutic development spectrum, without investing in physical infrastructure or capital development.

The VPCRC consortium members encompass surgical, oncological, radiological, and pathological prostate cancer treatment and diagnostic services as well as basic prostate cancer research. Its research groups are located amongst the collaborating institutions: The Royal Melbourne Hospital, The University of Melbourne, Ludwig Institute for Cancer Research, Monash University, The Peter MacCallum Cancer Centre and TissuPath Pty Ltd. Close links are also being developed with both the newly established Australian Prostate Cancer Research Centres in Victorian and Queensland.

The VPCRC facilitates linkages with its members by engaging closely with researchers and providing support for grant applications to Victorian based and national research grant bodies. In addition, the VPCRC acts as a vehicle for funding derived from government and other research funding bodies, as well as from philanthropic sources. It is the level of engagement with researchers in a consortium-based arrangement that distinguishes VPCRC from other funding bodies.

The Wesley Research Institute conducts clinical research that is making an immediate difference for patients everywhere.

Our vision is to make a lasting difference to health care practices by improving quality of life and patient care through medical research.

We promote medical research as the cornerstone of innovation in health care our dedication to education and mission to link clinical practice, medical research and science for better outcomes for patients worldwide.